Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Ren, ZG; Xu, JM; Bai, YX; Xu, AB; Cang, SD; Du, CY; Li, Q; Lu, YY; Chen, YJ; Guo, YB; Chen, ZD; Liu, BR; Jia, WD; Wu, J; Wang, JY; Shao, GL; Zhang, BX; Shan, YF; Meng, ZQ; Wu, JB; Gu, SZ; Yang, W; Liu, C; Shi, XT; Gao, ZY; Yin, T; Cui, JW; Huang, M; Xing, BC; Mao, YL; Teng, GJ; Qin, YR; Wang, JH; Xia, F; Yin, GW; Yang, Y; Chen, MX; Wang, Y; Zhou, H; Fan, J

Fan, J (corresponding author), Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai 200030, Peoples R China.

LANCET ONCOLOGY, 2021; 22 (7): 977

Abstract

Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepa......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索